TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24273151
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine 40 mg/m² once daily
Study: 24273151
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine 80 mg/m² four times daily
Study: 24273151
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine (various doses)
Study: 24273570
Drug: Newer antiepileptic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antiepileptic drugs (AEDs) in monotherapy or combination (24.6% of patients)
Study: 24273570
Drug: Older antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older antiepileptic drugs (AEDs) or combination of older and newer AEDs (75.4% of patients)
Study: 24273570
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment modifications
Study: 24275632
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug use
Study: 24276047
Drug: EZN-3042 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-3042 2.5 mg/kg/dose administered as a single agent on days -5 and -2, then in combination with a 4-drug reinduction chemotherapy on days 8, 15, 22, and 29.
Study: 24276047
Drug: EZN-3042 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-3042 2.5 mg/kg/dose (single agent)
Study: 24276047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EZN-3042 with intensive reinduction chemotherapy
Study: 24277073
Drug: Imatinib (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (single-agent course following induction)
Study: 24277073
Drug: Pre-imatinib standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-imatinib standard treatment
Study: 24283202
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg BID, with potential increase to 10 mg BID
Study: 24283202
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg BID
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination in patients treated with anti-TNF monoclonal antibody infliximab or adalimumab
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination in patients not treated with anti-TNF agents
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination in patients treated with ≥2 immunosuppressants
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination in patients treated with <2 immunosuppressants
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination comparing anti-TNF alone with anti-TNF and other immunosuppressants
Study: 24284413
Drug: HAV vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccination in patients receiving anti-TNF therapy
Study: 24285015
Drug: Doxorubicin HCl
Normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin HCl liposome injection (DLI) 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by Bexarotene 300 mg/m(2) orally for 16 weeks
Study: 24285015
Drug: Bexarotene 300
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene 300 mg/m(2) orally for 16 weeks
Study: 24287082
Drug: Bone Marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Marrow Mononuclear Cells (BMMC) infusion
Study: 24287733
Drug: Drug-related skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related skin disorders
Study: 24289141
Drug: Oral paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral paliperidone extended-release (ER) 3 to 12 mg daily for 26 to 52 weeks
Study: 24289658
Drug: TIV/10 (seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV/10 (seasonal trivalent inactivated vaccine 2010)
Study: 24289658
Drug: Monovalent AS03-adjuvanted
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine
Study: 24289796
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration during labor
Study: 24291380
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) therapy
Study: 24293774
Drug: Depot GnRHa
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot GnRHa (leuprolide 3.75-mg)
Study: 24294924
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 ug/day
Study: 24295437
Drug: Histrelin implant
Normalized name: histrelin Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histrelin implant (50-mg subcutaneous annually)
Study: 24295572
Drug: Vorinostat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (100 mg or 200 mg, twice a day) initiated 10 days before haemopoietic stem-cell transplantation until day 100, in combination with standard immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimus (0.03 mg/kg a day, titrated to a goal level of 8-12 ng/mL, starting day -3 until day 180)
Study: 24296713
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose stimulation
Study: 24297771
Drug: Late PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late PCI with optimal medical therapy (OMT)
Study: 24297953
Drug: Fractionated (90)Y-ibritumomab
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fractionated (90)Y-ibritumomab tiuxetan (90Y-IT) administered in two doses of 11.1 MBq/kg, 8 to 12 weeks apart.
Study: 24298176
Drug: Thrombolysis administered
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis administered within 90 minutes of ictus
Study: 24303954
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biofilm pathogens and GCF biomarkers with clinical measures
Study: 24304924
Drug: Foods with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foods with added fiber (23 g/d)
Study: 24307695
Drug: High-throughput sequencing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-throughput sequencing (HTS) of T cell receptors (TCRB)
Study: 24311637
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg starting dose, maintenance dose between 12.5 mg and 50 mg depending on tolerability
Study: 24314292
Drug: RARα antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RARα antagonist Ro415253
Study: 24314346
Drug: G-allele carriers
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-allele carriers
Study: 24315990
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor antagonist exendin (9-39) (Ex-9)
Study: 24316314
Drug: Fermented Papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Papaya Preparation (FPP) 6g/day for 14 weeks
Study: 24319018
Drug: Detectable serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable serum AMH concentration at chemotherapy initiation
Study: 24319462
Drug: Arthrocentesis using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis using saline and sodium hyaluronate injections
Study: 24319489
Drug: Caraway extract
Normalized name: Caraway Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caraway extract (CE) 30 mL/day
Study: 24320967
Drug: Oral mucosal
Normalized name: Finafta Multi Oral Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal potentially malignant diseases (PMD) management
Study: 24321746
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of third party bone marrow-derived mesenchymal stromal cells (MSC)
Study: 24322398
Drug: β Blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β Blockers
Study: 24323026
Drug: Neratinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (200 mg) + Temsirolimus (25 mg)
Study: 24323026
Drug: Neratinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (160 mg) + Temsirolimus (50 mg)
Study: 24323468
Drug: Ertapenem dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem dosing regimens: 500 mg once daily, 750 mg once daily, 500 mg twice daily, and 1,000 mg once daily
Study: 24324590
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg, every other day for 12 weeks
Study: 24330670
Drug: Oral ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ATP supplementation (400 mg per day)
Study: 24330868
Drug: Lurasidone (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-120 mg/day)
Study: 24332512
Drug: Pidilizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidilizumab (3 mg/kg IV every 4 weeks for four infusions, plus eight optional infusions every 4 weeks) + Rituximab (375 mg/m² IV weekly for 4 weeks starting 17 days after first pidilizumab infusion)
Study: 24334158
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with low-molecular-weight heparin or factor Xa-inhibitors only during hospitalisation when LOS ≤5 days.
Study: 24334175
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg QD for 8 weeks in T1D-H group
Study: 24334175
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg QD for 8 weeks in T1D-N group
Study: 24335595
Drug: Cetuximab and
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab and radiotherapy (cetux-RT) added to perioperative chemotherapy (ECX)
Study: 24335595
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (ECX)
Study: 24337621
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on day 1, 80 mg on days 2-3), Ramosetron (0.6 mg on day 1), Dexamethasone (20 mg on day 1)
Study: 24339028
Drug: Volasertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (300 mg on day 1 every 3 weeks, escalated to 350 mg in cycle 2 if tolerated)
Study: 24342300
Drug: pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed (500 mg/m2 IV)
Study: 24342300
Drug: docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (75 mg/m2 IV)
Study: 24342407
Drug: Non-selective endothelin
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective endothelin receptor antagonist
Study: 24343893
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (900 mg once weekly for 3 weeks)
Study: 24343893
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (600 mg once daily for 10 scheduled doses)
Study: 24343893
Drug: Raltegravir alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir alone (400 mg every 12 h for 4 days)
Study: 24344220
Drug: LMP-CTLs as
Normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMP-CTLs as adjuvant therapy
Study: 24347462
Drug: ABT-751 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-751 (200 mg/m² PO daily × 7 days every 21 days)
Study: 24349052
Drug: Ataluren 4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren 4, 4, 8 mg/kg three times per day
Study: 24349052
Drug: Ataluren 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren 20, 20, 40 mg/kg
Study: 24349052
Drug: Ataluren (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (all doses)
Study: 24349086
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g per day of ALA
Study: 24349334
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily for 7 days
Study: 24349470
Drug: PRS-050 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS-050 at 0.1 mg/kg to 10 mg/kg by IV
Study: 24349470
Drug: PRS-050 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRS-050 infusion
Study: 24351073
Drug: Serum CXCL-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CXCL-9 levels in antibody-positive women with a history of abortions
Study: 24351073
Drug: Serum CXCL-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CXCL-11 levels in antibody-positive women with a history of abortions
Study: 24351336
Drug: lenalidomide monotherapy
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide monotherapy
Study: 24351336
Drug: lenalidomide/cetuximab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide/cetuximab combination treatment
Study: 24352251
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day as maintenance therapy after cCRT
Study: 24352795
Drug: MLN8237 (alisertib)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN8237 (alisertib) ECT 50 mg BID for 7 days in 21-day cycles
Study: 24355090
Drug: Two-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose schedule (M 0-6)
Study: 24355090
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule (M 0-1-6)
Study: 24355487
Drug: Anastrozole therapy
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole therapy
Study: 24355920
Drug: Intravenous mangafodipir
Normalized name: mangafodipir
DrugBank: Mangafodipir (DB06796)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mangafodipir
Study: 24356623
Drug: Erlotinib 100
Normalized name: erlotinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 100 mg orally daily (maximally tolerated dose)
Study: 24356623
Drug: Erlotinib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib added to infusional 5-FU 225 mg/M2/day, bevacizumab 5 mg/kg, and radiation 50.4 Gy in 28 fractions
Study: 24356628
Drug: High p-AKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High p-AKT expression group with concurrent Epstein-Barr virus positivity
Study: 24356787
Drug: PHiD-CV booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV booster dose co-administered with DTPa booster dose
Study: 24356787
Drug: 2-dose catch-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose catch-up with PHiD-CV (first dose co-administered with DTPa booster dose)
Study: 24358067
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 75 mg twice daily plus omeprazole 20 mg daily
Study: 24359635
Drug: New antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antipsychotic monotherapy treatment initiated within 2 weeks prior to enrollment
Study: 24359635
Drug: New antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antipsychotic monotherapy treatment
Study: 24359972
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (max CGM glucose value ≥ 11 mmol/l)
Study: 24359972
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (max CGM glucose value < 11 mmol/l)
Study: 24360789
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment, mean final dose 0.6 (0.25) mg
Study: 24361681
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir monotherapy (MtDRV/rtv)
Study: 24362550
Drug: Triapine (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triapine (105 mg/m²/day) followed by fludarabine (30 mg/m²/day) daily for 5 consecutive days
Study: 24363672
Drug: Chemomechanical caries
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical caries removal with Papacarie gel
Study: 24363760
Drug: Oral arginine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral arginine, peripheral TPN
Study: 24366423
Drug: Erythritol 36
Normalized name: Erythritol
DrugBank: Erythritol (DB04481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol 36 g/day as an orange-flavored beverage for 4 weeks
Study: 24366583
Drug: Melatonin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (4 mg) twice daily until birth
Study: 24368064
Drug: Twice-weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly gemcitabine (starting dose 15 mg/m², escalated to 20, 25, and 30 mg/m²) and cisplatin (CDDP 20 mg/m²/day over 4 days every 21 days) with concomitant radiation therapy (63 Gy in 1.8 fractions)
Study: 24368064
Drug: Twice-weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly gemcitabine (30 mg/m²)
Study: 24369094
Drug: Belinostat (PXD101)
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat (PXD101) administered intravenously at a dose of 1000 mg/m² daily on days 1-5 of a 21-day cycle until progression or unacceptable toxicity.
Study: 24369412
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg adalimumab every other week
Study: 24372730
Drug: Salvage partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage partial low-dose rate brachytherapy
Study: 24372730
Drug: Initial low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial low-dose rate brachytherapy
Study: 24373120
Drug: Caspofungin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin + liposomal amphotericin B (L-AmB)
Study: 24373120
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (combo)
Study: 24373343
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estrogen-alone and estrogen plus progestin)
Study: 24375324
Drug: Waist and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waist and subcutaneous adipose tissue (SAT)
Study: 24377099
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine in Montanide adjuvant
Study: 24377099
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine in Montanide adjuvant with GM-CSF
Study: 24378417
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/day by mouth for up to 12 months, with possible dose escalation to 600 mg/day at 3 months if stable.
Study: 24379928
Drug: Rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy (40 mg/d)
Study: 24380752
Drug: drug-targeting nebulization
Normalized name: NEBULIZER
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug-targeting nebulization
Study: 24381190
Drug: Pre-bronchodilator FEV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator FEV1
Study: 24381226
Drug: Otlertuzumab administered
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Otlertuzumab administered intravenously, ranging from 0.03 to 20 mg/kg in dose-escalation phase and 10 to 30 mg/kg in dose-expansion phase, weekly for up to 8 weeks followed by 1 dose per month for 4 months.
Study: 24383664
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate supplementation (220 mg per capsule, 2 capsules per day for 3 months)
Study: 24383664
Drug: Fertile controls
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertile controls (no treatment)
Study: 24384108
Drug: 14-day adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day adhesive patch monitor
Study: 24384609
Drug: Budesonide 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1,500 μg
Study: 24384609
Drug: Budesonide 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1,500 μg (in cases with high baseline clinical score ≥13)
Study: 24385516
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (B6) administered orally starting at 5 mg/kg body weight per day, increasing by 5 mg/kg every 6 weeks up to 20 mg/kg per day at week 24.
Study: 24386300
Drug: Budesonide/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 400/12 µg twice a day for 4 weeks
Study: 24387695
Drug: MK-2206 45
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 45 mg QOD with carboplatin (AUC 6.0) and paclitaxel 200 mg/m2